Skip to main content

Drug Interactions between delavirdine and fosphenytoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fosphenytoin delavirdine

Applies to: fosphenytoin and delavirdine

CONTRAINDICATED: Coadministration with potent inducers of CYP450 3A4 such as phenytoin may significantly decrease the plasma concentrations of delavirdine, which is primarily metabolized by the isoenzyme. Population pharmacokinetic data from efficacy studies showed that delavirdine plasma trough concentration (Cmin) was reduced by approximately 90% in patients (n=8) treated with various dosages of phenytoin, phenobarbital, and/or carbamazepine who were given delavirdine 300 to 400 mg three times a day.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of delavirdine with phenytoin or fosphenytoin is considered contraindicated.

References (3)
  1. (2001) "Product Information. Dilantin (phenytoin)." Parke-Davis
  2. (2001) "Product Information. Cerebyx (fosphenytoin)." Parke-Davis
  3. (2001) "Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer